Re: Rep triggered e-mails
As a follow on question, in the the same context as described previously (no branding or drug mention in the e-mail itself, what would be the naming convention for clinical reprints attached to an RTE? For clinical reprints for which we have already obtained PAAB approval to distribute for a brand, would it suffice to have the author name, journal and year e.g., "Smith, NEJM 2015" with no fair balance needed? Could the acronym of the study name be included e.g., "Smith, NEJM 2015 PRTII study", and still require no fair balance?
Thanks again
L
Laurelea
@Laurelea
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Posts
-
Attachment of clinical reprints in an RTE -
Rep triggered e-mailsRe: edirect campaign to HCP
I read in a previous post that reps that promote more than one brand to the same HCP may include attachments for more than one brand to their RTE.If the subject line, body of the e-mail and sign-off do not contain any brand name or branding whatsoever, is it necessary to include any fair balance at all? The only place a brand name would appear would be in the file name, E,g, brandxpatient supporttool.pdf. We would assume not, because there are no claims, and each tool would have the fair balance appropriate to that tool, but would appreciate confirmation.
(We are aware that branded and unbranded tools cannot be included in the same RTE).
Thanks, L.